secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001933414-24-000006
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics raises $120M in private placement; funds lorundrostat development
--------------------------------------------------------------------------------

- PIPE of ~8.9M shares/pre-funded warrants at $13.50/share; gross proceeds ~$120M.
- Lead investors TCGX and RA Capital Management, joined by OrbiMed, Venrock, Samsara, and others.
- Net proceeds to fund R&D of lorundrostat (aldosterone-driven hypertension/CKD) and general corporate purposes.
- PIPE expected to close Feb 12, 2024; BofA Securities and Evercore as placement agents.
- Registration statement to be filed within 60 days of closing for resale of shares and warrant shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000006/0001933414-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000006/mlys-20240207.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer